Reuben Jonathan Miller

Feb 6, 2025 | ionanalytics.com | Rupert Cocke |Reuben Jonathan Miller |Carlos Martinez

Podcast China’s antitrust regulator SAMR’s review of US-backed mergers could become politicizedChinese authorities are probing into Apple and Google, and have taken other non-tariff retaliatory measuresSynopsys [NASDAQ:SNPS] could find its plan to take over Ansys [NASDAQ:ANSS] faces more intense regulatory scrutiny in China as a result of US President Donald Trump’s announcement of new tariffs on the Asian giant over the weekend.

Feb 4, 2025 | ionanalytics.com | Reuben Jonathan Miller |Kevin Ketcham |Kevin McCaffrey |Carlos Martinez

News (Intelligence) Foreign regulatory reviews of US-backed deals may emerge as easy targets for retaliationAmong neighbors and longtime trade adversary, China represents most acute threatPending deals such as Ansys/Synopsys represent potential bellwethersThe world knew that US President Donald Trump planned to use tariffs as an economic cudgel and businesspeople worldwide have been abuzz discussing the matter for months.

Jan 23, 2025 | ionanalytics.com | Reuben Jonathan Miller |Carlos Martinez

News (Intelligence) A new frame of analysis is needed for Trump’s enforcement dispositionWillingness to bend agencies to achieve broader administration objectives keyShutterstock/Getty deal carries with it traditional risk, as well as potential retribution against Koch familyHell or High Water is a weekly column that offers commentary from our editorial team on the main deals undergoing regulatory reviews as well as the broader enforcement environment.